Nanogen - PharmXpert Academy

Conclusions
The naturally occurring glycoalkaloids solasodine glycosides
(BEC) have anticancer activity in cell culture, animals and in
humans. Specific endogenous lectins which are present in the
plasma membranes of cancer cells recognize and bind the sugar
moiety of BEC. BEC is subsequently internalised and causes
cell death by destroying the lysosome. This mode of action
is very different than with other anticancer drugs (which are
non-specific, destroying normal cells as well) and work on the
nuclear contents such as the DNA or RNA of cells.
Independent centres show that BEC5 Curaderm is virtually
100% effective for treating skin cancers if the lesions are
treated for long enough.
The cosmetic result of skin cancer treatment with BEC5
Curaderm is excellent and lesions treated appropriately with
BEC5 Curaderm result in no recurrence.
The amount of BEC in Curaderm is very small. One averagesized
eggplant fruit (300g) contains the same amount of BEC
as 60 tubes of Curaderm! Thus, BEC5 Curaderm is safe as
shown by the many published studies. Ergo, BEC5 Curaderm is
an ideal therapy for skin cancers.
Here are examples of patients before, during and after
treatment with BEC5 Curaderm. A typical treatment period
from start to finish is 8 weeks.
References
3. Cham BE and Meares HM. Glycoalkaloids from Solanum
sodomaeum are effective in the treatment of skin cancers in man.
Cancer Letters 1987; 36: 111-118.
4. Cham BE. Monograph on BEC. Drugs of the Future 1988; 13:
714-716.
5. Cham BE and Daunter B. Curaderm (anti-neoplastic) launched in
Australia. Drug News Perspectives 1989; 2: 112.
6. Daunter B and Cham BE. Solasodine glycosides. In vitro
preferential cytotoxicity for human cancer cells. Cancer Letters
1990; 55: 209-220.
7. Cham BE and Daunter B. Solasodine glycosides. Selective
cytotoxicity for cancer cells and inhibition of cytotoxicity by
rhamnose in mice with Sarcoma 180 activity. Cancer Letters 1990;
55: 221-225.
8. Cham BE and Daunter B. Topical treatment of pre-malignant and
malignant skin cancers with Curaderm. Drugs of Today 1990; 26:
55-58.
9. Cham BE, Daunter B, Evans RA. Topical treatment of malignant
and premalignant skin lesions by very low concentrations of a
standard mixture (BEC) of solasodine glycosides. Cancer Letters
1991; 59: 183-192.
10. 10. Cham BE. Solasodine glycosides: a new modality for
cancer. In: Walker, MS, ed. Proceedings of the third Oceania
Symposium on complementary medicine. Queensland: Bio
Concepts Publishing 1992; 30-36.
11. Cham BE. The efficacy and mode of action of solasodine
glycosides (BEC) on cancer cells. In: Walker MS, ed. Proceedings
of the fourth Oceania Symposium on complimentary medicine.
Queensland: Bio Concepts Publishing 1993; 41-51.
12. Cham BE. Solasodine glycosides as anti-cancer agents: Pre-clinical
and clinical studies. Asia Pacific Journal of Pharmacology 1994; 9:
113-118.
13. Chang LC, Tsai TR, Wang JJ, Lin CN and Kuo KW. The rhamnose
moiety of solamargine plays a crucial role in triggering cell death
by aptosis. Biochemistry Biophysics Research Communication
1998; 242: 21-25.
14. Hsu SH, Tsai TR, Lin CN, Yen MH and Kuo KW. Solamargine
purified from Solanum incanum Chinese herb triggers gene
expression of human TNFR1 which may lead to cell aptosis.
Biochemistry Biophysics Research Communication 1996; 229: 1-5.
15. Kuo KW, Hsu SH, Li YP, Lin WL, Chang LC, Lin CC, Lin CN
and Sheu HM. Anticancer activity evaluation of the Solanum
glycoalkaloid solamargine. Triggering aptosis in human hepatoma
cells. Biochemistry Pharmacology 2000; 60: 1865-1973.
16. Nakamura T, Komori C, Lee Y, Hashimoto F, Yahara S, Nohara T
and Ejina A. Cytotoxic activities of Solanum steroidal glycosides.
Biology Biopharmacy Bulletins 1996; 19: 564-566.
17. Roddick JG, Weissenberg M and Leonard AL. Membrane
disruption and enzyme inhibition of naturally-occurring and
modified chaco-triose-containing Solanum steroidal glycoalkaloids.
Phytochemistry 2001; 56: 603-610.
18. Solbec Pharamaceuticals Limited, Australia. www.solbec.com.au
19. Jones PG and Fenwick GR. The glycoalkaloid content of some
edible Solanaceous fruits and potato products. Journal of Science
and Food Agriculture 1981; 32: 419-421.
1. Cham BE, Gilliver M and Wilson L. Antitumour effects of
glycoalkaloids isolated from Solanum sodomaeum. Planta Medica
1987; 53: 34-36.
2. Cham BE and Wilson L. HPLC of glycoalkaloids from Solanum
sodomaeum. Planta Medica 1987; 53: 59-62.
14
www.antiaging-systems.com // Order hotline: 1-866-800-4677 // e-mail: ias@antiaging-systems.com